Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • YC-1: Practical Guide for Cancer and Hypoxia Research Workfl

    2026-04-12

    YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol: Applied Workflows for Cancer and Hypoxia Research

    What This Product Solves

    YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol (SKU B7641) is a synthetic, high-purity small molecule used primarily in cancer biology and hypoxia research. It is characterized by its dual action as a soluble guanylyl cyclase (sGC) activator and as an inhibitor of hypoxia-inducible factor-1α (HIF-1α) at the post-transcriptional level. This profile fills a critical gap in experimental models that aim to dissect the molecular mechanisms of tumor adaptation to hypoxic microenvironments, as well as vascular and platelet function studies. YC-1's ability to block HIF-1α transcriptional activity is particularly relevant in investigating tumor angiogenesis inhibition and survival pathways under oxygen deprivation.

    Researchers can leverage YC-1 to interrogate pathways regulating apoptosis and cancer progression, with particular utility in hepatoma and other solid tumor models where HIF-1α and its downstream effectors are upregulated. Its sGC activation properties also extend its application to studies on vascular tone and platelet aggregation. However, its use is strictly limited to laboratory research settings, as it is not intended for diagnostic or therapeutic use in humans.

    Protocol Parameters

    • Compound Solubility Screening | ≥30.4 mg/mL in DMSO | Pre-experimental solution preparation | Ensures compound is fully dissolved for accurate dosing and reproducibility in cell-based or biochemical assays | product_spec (source)
    • Compound Solubility Screening | ≥16.2 mg/mL in ethanol | Alternative solvent for experiments incompatible with DMSO | Provides flexibility in workflow setup for solvent-sensitive assays | product_spec (source)
    • Storage Conditions | Room temperature (solid), avoid long-term solution storage | All applications | Maintains compound stability and prevents degradation, especially in solution | product_spec (source)
    • Typical Working Concentration Range | 1–50 µM (prepare fresh) | Cell-based/in vitro studies | Based on standard research practice for small-molecule inhibitors; optimal range should be confirmed by pilot titration | workflow_recommendation
    • Vehicle Control | 0.1%–0.5% DMSO final concentration | Control groups in cellular assays | Minimizes solvent effects while maintaining compound solubility; always match vehicle concentration across conditions | workflow_recommendation

    Workflow Setup and QC Checklist

    For robust and reproducible results when working with YC-1, adhere to the following setup and quality control steps:

    1. Compound Preparation: Dissolve YC-1 directly in DMSO or ethanol at the maximal solubility recommended in the product dossier. Prepare aliquots to avoid repeated freeze-thaw cycles.
      Note: YC-1 is insoluble in water; do not attempt aqueous dissolution without prior solvent dilution.
    2. Solution Stability: Store dry powder at room temperature. Prepare working solutions fresh before each experiment; do not use solutions stored for more than 24 hours, as per product specification.
    3. Assay Controls: Always include both vehicle-only and untreated controls to distinguish compound-specific effects from solvent background.
    4. Concentration Titration: If first using YC-1 in a new cell line or model, perform a pilot dose-response study to identify the minimum effective concentration for inhibition of HIF-1α transcriptional activity or sGC activation.
    5. Documentation: Record lot number, preparation date, and solvent details for each batch to ensure traceability.

    For detailed workflow optimization, see the internal article "YC-1: Applied Workflows and Troubleshooting in Hypoxia and Cancer Research", which expands on protocol design and common troubleshooting strategies specific to APExBIO YC-1.

    Common Failure Modes and Fixes

    • Precipitation in Solution: If turbidity appears after dilution, verify that final DMSO or ethanol concentration remains above the compound's solubility threshold. For aqueous applications, sequentially dilute YC-1 from a high-concentration DMSO stock into culture media, ensuring rapid mixing to prevent precipitation.
    • Inconsistent Biological Response: Confirm solution freshness and storage conditions. Degraded or improperly stored compound may show variable activity. Always prepare fresh working solutions as recommended.
    • High Background or Non-specific Effects: Ensure that vehicle control concentrations match those in treated samples. Excessive solvent may impact cell viability or assay readouts.
    • Batch-to-Batch Variation: Use high-purity, single-lot YC-1 from APExBIO; document all lot numbers. If switching lots, re-validate dose-response where feasible.

    See also "YC-1: Soluble Guanylyl Cyclase Activator & HIF-1α Inhibitor for Tumor Studies" for additional troubleshooting insights and comparative protocol notes.

    Scope and Limitations

    YC-1 is designed for scientific research, specifically in the areas of inhibition of hypoxia-inducible factor 1 transcriptional activity, tumor angiogenesis inhibition, and apoptosis and cancer biology research. Its use is strongly supported in cell-based and in vitro studies, particularly in models investigating hypoxia signaling pathways and vascular responses. However, the compound is not water-soluble, which restricts its application in certain aqueous-only protocols. Long-term storage of working solutions is not recommended due to potential degradation and loss of activity. Researchers should also be aware that numeric efficacy claims are based on product specifications and workflow recommendations—not on clinical or in vivo trial data.

    YC-1 is not suitable for diagnostic, therapeutic, or clinical applications. Always verify compatibility with specific cell lines or assay systems before full-scale use.

    Conclusion

    YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is a well-characterized research tool for dissecting the molecular underpinnings of hypoxia response and tumor biology. Its dual activity profile as an sGC activator and HIF-1α inhibitor streamlines complex pathway analysis in cancer and vascular studies. Strict attention to solubility, storage, and control setup ensures reproducibility and reliability. For more details or to request high-purity product for your workflow, visit YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol at APExBIO.